Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by CenterBook Partners LP

CenterBook Partners LP increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 307.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,464 shares of the biopharmaceutical company’s stock after purchasing an additional 36,556 shares during the quarter. CenterBook Partners LP’s holdings in Catalyst Pharmaceuticals were worth $1,131,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Deerfield Management Company L.P. grew its position in Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares during the period. American Century Companies Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after acquiring an additional 770,198 shares in the last quarter. Fundsmith LLP grew its holdings in shares of Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after acquiring an additional 654,721 shares during the period. Glenmede Investment Management LP increased its stake in Catalyst Pharmaceuticals by 781.8% in the 3rd quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after purchasing an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Catalyst Pharmaceuticals by 30.6% in the 2nd quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after purchasing an additional 554,200 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $31.34 on Thursday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The stock’s fifty day simple moving average is $28.89 and its 200-day simple moving average is $25.53. The company has a market capitalization of $3.84 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.95 and a beta of 0.74.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CPRX shares. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. HC Wainwright cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $35.00 to $31.50 in a research report on Thursday, May 28th. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).